Back to today’s briefing

Story perspectives

FDA Resumes Elevidys Shipments, Sarepta Stock Soars

7/31/2025

50 7

Summary

Story summary

Sarepta Therapeutics' stock soared as the FDA greenlit the resumption of shipments for Elevidys, a gene therapy aimed at ambulatory Duchenne muscular dystrophy patients. This comes after a two-week halt due to safety worries tied to patient fatalities. While the news is promising, the road ahead is fraught with challenges over long-term acceptance and safety evaluations.

History

Historical Context

In 2012, the FDA approved Glybera, the first gene therapy for a rare genetic disorder, lipoprotein lipase deficiency, affecting 1 in 1 million people. This milestone highlighted the complexities of treating rare diseases. The recent approval of Sarepta Therapeutics' Elevidys in June 2023 for Duchenne muscular dystrophy reflects ongoing debates about gene therapy safety, especially following patient fatalities linked to similar treatments.

1 of 2

Story summary

Sarepta Therapeutics' stock soared as the FDA greenlit the resumption of shipments for Elevidys, a gene therapy aimed at ambulatory Duchenne muscular dystrophy patients. This comes after a two-week halt due to safety worries tied to patient fatalities. While the news is promising, the road ahead is fraught with challenges over long-term acceptance and safety evaluations.

1 / 2